Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR Inks Domestic Production Deal for AstraZeneca COVID-19 Vaccine Solution
January 6, 2021
- Takeda Closes Sales of 16 Non-Core Meds to Germany’s Cheplapharm
January 6, 2021
- Hisamitsu’s Osteoarthritis Patch Drug Enters PIII in US
January 6, 2021
- Kobayashi Kako Corrects Number of Health Damages from Itraconazole Mix-Up
January 6, 2021
- Drug Makers, Wholesalers Brace for Second Emergency Declaration in Japan
January 6, 2021
- Ono, Prof. Honjo Disagree About Validity of Patent Royalty Rate for Opdivo
January 6, 2021
- Daiichi Sankyo Files Sakigake-Designated Oncolytic Virus in Japan After Overcoming Manufacturing Issues
January 6, 2021
- Fuji Pharma Files Natural Progesterone Drug in Japan for Menopausal Disorders
January 5, 2021
- Kobayashi Kako Adds 2 APIs to Class II Recall List, Meiji/Elmed Products
December 28, 2020
- AstraZeneca to Accelerate Growth of Forxiga with Heart Failure Use, Gets Head Start in Arena before Rival Jardiance
December 28, 2020
- US FDA Lifts Clinical Hold for Audentes’ Gene Therapy AT132: Astellas
December 28, 2020
- Opdivo Misses Primary Targets in PIII for Glioblastoma Multiforme: BMS
December 28, 2020
- Kobayashi Kako Recalls 12 More APIs after On-Site Inspections
December 25, 2020
- Daiichi Sankyo Espha Stops Supply of 3 APIs after Kobayashi Kako Mix-up
December 25, 2020
- Mitsubishi Tanabe to Revise Company Rules for Common-Law Marriages, Same-Sex Relationships
December 25, 2020
- 49 APIs Listed in 2020, 10 Billion-Plus Yen Peak Sales Projected for 17: Jiho Tally
December 24, 2020
- Kyowa Kirin Adjusts Shipment of Depakene after Kobayashi Kako Drug Mix-Up
December 24, 2020
- Sales Rep Promotions Down Both in GP, HP Markets in October: Intage
December 24, 2020
- Sosei, Captor to Collaborate on Targeted GPCR Degradation
December 23, 2020
- Axcelead Looks to Unearth New Drugs from Takeda’s Legacy Assets, 5-Plus Collaborations Ongoing
December 23, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…